ty nakers
82-8000 USAF VIP 747 on ground at JBA from Toledo Express Airport, OH
Landed about 15-20 minutes ago-delay icydk
chek't
Syneos Health Inc. sold by Chief Executive Officer & Director: $223.18m-Sept 17
09/17/2020
On September 15, 2020, Syneos Health, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (the "Underwriters") and the selling stockholders named therein (the "Selling Stockholders"). Pursuant to the Underwriting Agreement, the Selling Stockholders agreed to sell 7,000,000 shares of the Company's common stock, $0.01 par value per share (the "Common Stock"), to the Underwriters at a price of $59.26 per share, to be offered to the public at a price to of $59.75 per share. The Company has also agreed to repurchase from the underwriters 506,244 shares of common stock being sold by the Selling Stockholders at a per-share purchase price equal to the price payable by the Underwriters to the Selling Stockholders.
https://www.marketscreener.com/quote/stock/SYNEOS-HEALTH-INC-40082421/news/SYNEOS-HEALTH-INC-Entry-into-a-Material-Definitive-Agreement-Financial-Statements-and-Exhibits-31312339/
Syneos Health Inc. is a fully integrated biopharmaceutical solutions providing company. The Company offers both stand-alone and integrated biopharmaceutical product development solutions through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. It brings together approximately 24,000 clinical and commercial professionals with the ability to support customers in more than 110 countries. Together it shares insights, leverages latest technologies and apply advanced business practices to deliver important therapies to patients. Number of employees : 24 000 people.
https://www.marketscreener.com/quote/stock/SYNEOS-HEALTH-INC-40082421/company/
John Maldonado-Managing Partner Advent International Corporation Boston
John Maldonado joined Advent in 2006 focusing on buyouts in the healthcare, financial and business services sectors. His previous private equity experience includes positions at both Bain Capital and Parthenon Capital. John began his career as a Consultant with The Parthenon Group, a leading strategy consulting firm.
Alistair John Macdonald is a businessperson who has been the head of 5 different companies and occupies the position of Chief Executive Officer & Director at Syneos Health, Inc. and Chief Executive Officer & Director at Syneos Health LLC (a subsidiary of Syneos Health, Inc.). Mr. Macdonald is also on the board of Syneos Health Branches Ltd., Syneos Health UK Ltd., Syneos Health Clinical Development Services Ltd. and Martello (Holdings) Ltd. and Chairman at Association of Clinical Research Organizations and Chief Executive Officer & Director at Syneos Health LLC. In the past Mr. Macdonald held the position of Chief Executive Officer at inVentiv Health, Inc., Chief Executive Officer & Director at INC Research Holdings, Inc., Managing Director at Wilkerson Group and Vice President-Corporate Development at Quintiles Transnational Corp.
https://www.wsj.com/market-data/quotes/SYNH/company-people/executive-profile/12469785
https://www.adventinternational.com/team/
https://www.finviz.com/insidertrading.ashx?oc=1544918&tc=7&b=2
https://www.sec.gov/Archives/edgar/data/1544918/000114036120021061/xslF345X03/form4.xml
o7